Finance
e-Newsletter
Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

Drug firms say they'll take closer look at the docs they pay

Propublica, November 18, 2010

Several of the nation's largest pharmaceutical companies said they plan to tighten screening of physicians who promote their drugs after ProPublica reported last month that more than 250 of them had been sanctioned for misconduct.

Eli Lilly and Co. said that next year, for the first time, it would hire an outside firm to search for state disciplinary actions against its hired speakers and advisers. Lilly, the seventh-largest company by U.S. prescription sales, did not previously conduct such screening and was unaware of the dozens of actions ProPublica found against its speakers.

"Your reporting has raised valid and important questions, which we have taken steps to address," spokesman J. Scott MacGregor said in a statement.

Comments are moderated. Please be patient.

1 comments on "Drug firms say they'll take closer look at the docs they pay"


Daniel Haszard (11/19/2010 at 2:24 AM)
Glaxo whistle-blower gets $96 million. The case with the Zyprexa scandal is that Eli Lilly drug company pleaded guilty to criminal wrongs ("viva Zyprexa" campaign) the Zyprexa saga was rotten through and through. Eight Lilly EMPLOYEES got millions each as supposed informant 'whistle blowers'.Lawyers on BOTH sides got millions and millions......most patient claimants who got sick are 'mentally challenged' and less able to advocate for themselves. The Class action Lawsuits in the US had payouts of $85,000 BUT the lawyers got 45 percent and then the govt got most of the rest for having to take care of the victim/patients medical expenses.Soooo,,,,$85K turned into about $9,000 for Zyprexa claimants many had their food stamps and other state benefits taken away because of their *windfall profit* making them worse off in the end. * Daniel Haszard Zyprexa victim activist and patient who got diabetes from it.